Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LLH135
- Development stage
- Preclinical
- Lead developer
- Universidad de Guadalajara
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**LLH135** is an orally administered, three-strain probiotic microbial mixture comprising *Limosilactobacillus fermentum* LH01, *Limosilactobacillus reuteri* LH03, and *Lactiplantibacillus plantarum* LH05, originally isolated from human milk. It has been evaluated preclinically in 6-hydroxydopamine-induced murine hemiparkinsonism models, where four weeks of administration improved motor-function measures, reduced oxidative-stress markers and glial activation, and mitigated blood-brain and gut-barrier permeability changes. The proposed therapeutic activity is modulation of the microbiota-gut-brain axis with downstream antioxidant, anti-neuroinflammatory, and neuroprotective effects; it has not been established as a human clinical treatment for Parkinson's disease. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006709/))
- Other names
- Lactiplantibacillus plantarum LH05 + Limosilactobacillus fermentum LH01 + Limosilactobacillus reuteri LH03Lactobacillus fermentum LH01 + Lactobacillus reuteri LH03 + Lactobacillus plantarum LH05
Beyond the preview
Go deeper on LLH135.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LLH135.